Plus therapeutics provides business update on cnside diagnostics subsidiary

U.s. commercial rollout of novel diagnostic platform to begin second half 2025 underserved cns cancer diagnostic u.s. market opportunity estimated to be in excess of $6 billion management to host a conference call today at 9am et houston, june 26, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, will provide a business update for its wholly-owned subsidiary, cnside diagnostics, llc (“cnside”). the proprietary cnside cerebrospinal fluid (csf) assay platform is designed and intended for patients suspected of having central nervous system cancer metastases (cns mets).
PSTV Ratings Summary
PSTV Quant Ranking